. Lawton, Androgen Receptor Expression in Estrogen Receptor-Negative Breast Cancer. Immunohistochemical, Clinical, and Prognostic Associations, American Journal of Clinical Pathology, vol.120, issue.5, pp.725-756, 2003.

A. Cancer, S. Manual, |. Stephen-edge, and |. Springer, Accessed November 18, p.9780387884400, 2015.

S. Ali and R. C. Coombes, Estrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance, Journal of Mammary Gland Biology and Neoplasia, vol.5, issue.3, pp.271-81, 2000.
DOI : 10.1023/A:1009594727358

C. Jeffrey, Y. Roeser, and . Chen, AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer, The New England Journal of Medicine, vol.371, issue.11, pp.1028-1066, 2014.

E. Warner, Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2014.

G. Arpino, V. J. Bardou, G. M. Clark, and R. M. Elledge, Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome, Breast Cancer Research, vol.8, issue.3, p.149, 2004.
DOI : 10.1002/1097-0142(197507)36:1<1::AID-CNCR2820360102>3.0.CO;2-4

Y. Asano, S. Kashiwagi, N. Onoda, K. Kurata, T. Morisaki et al., Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer, British Journal of Cancer, vol.18, issue.1, pp.14-20, 2016.
DOI : 10.5858/arpa.2013-0953-SA

U. Asghar, M. T. Herrera-abreu, R. Cutts, I. Babina, A. Pearson et al., Identification of Subtypes of Triple Negative Breast Cancer (TNBC) That Are Sensitive to CDK4/6 Inhibition, Journal of Clinical Oncology, vol.33, issue.11098, pp.147443-156, 2015.

G. Attard, A. S. Belldegrun, and J. S. Bono, Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer, BJU International, vol.84, issue.9, pp.1241-1287, 2005.
DOI : 10.1016/0960-0760(94)90131-7

G. Attard, J. F. Swennenhuis, D. Olmos, A. H. Reid, E. Vickers et al., Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer, Cancer Research, vol.69, issue.7, pp.2912-2930, 2009.
DOI : 10.1158/0008-5472.CAN-08-3667

M. A. Augello, E. Theresa, K. E. Hickey, and . Knudsen, FOXA1: master of steroid receptor function in cancer, The EMBO Journal, vol.209, issue.19, pp.3885-94, 2011.
DOI : 10.1038/emboj.2011.340

A. M. Carter, M. S. Frederick, and . Lawrence, Sequence Analysis of Mutations and Translocations across Breast Cancer Subtypes, Nature, vol.486, issue.7403, pp.405-414, 2012.

G. Banneau, M. Guedj, G. Macgrogan, I. De-mascarel, V. Velasco et al., Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations, Breast Cancer Research, vol.15, issue.4, pp.10-1186, 2010.
DOI : 10.1038/nm.2000

URL : https://hal.archives-ouvertes.fr/inserm-00663724

C. S. Higano and P. Iversen, Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, The New England Journal of Medicine, vol.371, issue.5, pp.424-457, 2014.

. Anderson, FOXA1 Represses the Molecular Phenotype of Basal Breast Cancer Cells, Oncogene, vol.32, issue.5, pp.554-63, 2013.

A. Berruti, V. Amoroso, F. Gallo, V. Bertaglia, E. Simoncini et al., Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies, Journal of Clinical Oncology, vol.32, issue.34, pp.3883-91, 2014.
DOI : 10.1200/JCO.2014.55.2836

P. Viens and D. Birnbaum, How Basal Are Triple-Negative Breast Cancers?, International Journal of Cancer, vol.123, issue.1, pp.236-276, 2008.

G. Berx, A. M. Cleton-jansen, F. Nollet, W. J. De-leeuw, M. Van-de-vijver et al., E-Cadherin Is a Tumour/Invasion Suppressor Gene Mutated in Human Lobular Breast Cancers, The EMBO Journal, vol.14, issue.24, p.6107, 1995.

S. N. Birrell, M. Lisa, J. M. Butler, G. Harris, W. D. Buchanan et al., Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer, The FASEB Journal, vol.21, issue.10, pp.2285-93, 2007.
DOI : 10.1096/fj.06-7518com

F. M. Blows, E. Kristy, M. K. Driver, A. Schmidt, F. E. Broeks et al., Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies, PLoS Medicine, vol.12, issue.5, 2010.
DOI : 10.1371/journal.pmed.1000279.s011

M. Boer, J. A. De, P. Van-dijck, G. F. Bult, V. C. Borm et al., Breast Cancer Prognosis and Occult Lymph Node Metastases, Isolated Tumor Cells, and Micrometastases, JNCI Journal of the National Cancer Institute, vol.102, issue.6, pp.410-435, 2010.
DOI : 10.1093/jnci/djq008

H. Bonnefoi, A. Ducraux, S. Movarekhi, M. F. Pelte, S. Bongard et al., p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients, British Journal of Cancer, vol.1, issue.5, pp.750-55, 2002.
DOI : 10.1038/sj.bjc.6600105

H. Bonnefoi, T. Grellety, O. Tredan, M. Saghatchian, F. Dalenc et al., A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1), Annals of Oncology, vol.27, issue.5, pp.812-830, 2016.
DOI : 10.1093/annonc/mdw067

H. Bonnefoi, M. P. Bogaerts, L. Mauriac, P. Fumoleau, E. Brain et al., TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial, The Lancet Oncology, vol.12, issue.6, pp.527-566, 2011.
DOI : 10.1016/S1470-2045(11)70094-8

R. Bose, S. M. Kavuri, A. C. Searleman, W. Shen, D. Shen et al., Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer, Cancer Du Sein Infiltrant Non Métastatique -Questions D'actualités (Annexes) -Ref, pp.224-261, 2013.
DOI : 10.1158/2159-8290.CD-12-0349

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570596

A. Cancer, http://www.ecancer.fr/Expertises-et-publications/Catalogue-des-publications/Cancer-du-sein-infiltrant- non-metastatique-questions-d-actualites-annexes

F. Cardoso, A. Costa, L. Norton, E. Senkus, M. Aapro et al., ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2), Annals of Oncology, 2014.
DOI : 10.1016/j.breast.2014.08.009

URL : http://doi.org/10.1016/j.breast.2014.08.009

C. L. Carter, C. Allen, and D. E. Henson, Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, vol.45, issue.1, pp.181-87, 1989.
DOI : 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H

B. S. Carver, C. Chapinski, J. Wongvipat, H. Hieronymus, Y. Chen et al., Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer, Cancer Cell, vol.19, issue.5, pp.575-86, 2011.
DOI : 10.1016/j.ccr.2011.04.008

M. C. Cheang, K. Stephen, D. Chia, D. Voduc, S. Gao et al., Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer, JNCI Journal of the National Cancer Institute, vol.101, issue.10, pp.736-50, 2009.
DOI : 10.1093/jnci/djp082

L. E. Chia and . Shepherd, Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.18, issue.8, pp.2402-2414, 2012.

K. Chia, J. Ming, G. D. Liu, A. Francis, and . Naderi, A Feedback Loop between Androgen Receptor and ERK Signaling in Estrogen Receptor-Negative Breast Cancer, Neoplasia, vol.13, issue.2, pp.154-66, 2011.
DOI : 10.1593/neo.101324

K. Chia, M. O. Brien, M. Brown, and E. Lim, Targeting the Androgen Receptor in Breast Cancer, Current Oncology Reports, vol.14, issue.4, pp.4-10, 2015.
DOI : 10.1007/s11912-014-0427-8

J. Choi, S. H. Eun, S. J. Kang, Y. K. Lee, and . Bae, Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer, Annals of Surgical Oncology, vol.6, issue.1, pp.82-89, 2015.
DOI : 10.1245/s10434-014-3984-z

J. Choi, W. Jung, and J. S. Koo, Clinicopathologic Features of Molecular Subtypes of Triple Negative Breast Cancer Based on Immunohistochemical Markers, Histology and Histopathology, vol.27, issue.11, pp.1481-93, 2012.

M. Christgen, W. Patrick, and . Derksen, Lobular breast cancer: molecular basis, mouse and cellular models, Breast Cancer Research, vol.10, issue.1, 2015.
DOI : 10.1371/journal.pgen.1004285

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320436

A. Ciupek, Y. Rechoum, G. Gu, L. Gelsomino, A. R. Beyer et al., Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ER??-positive breast cancer, Breast Cancer Research and Treatment, vol.66, issue.Suppl 1, pp.225-262, 2015.
DOI : 10.1007/s10549-015-3609-7

N. J. Clegg, J. Wongvipat, J. D. Joseph, C. Tran, S. Ouk et al., ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment, Cancer Research, vol.72, issue.6, pp.1494-1503, 2012.
DOI : 10.1158/0008-5472.CAN-11-3948

H. Thürlimann, Senn, and Panel members Tailoring Therapies -Improving the Management of Early Breast Cancer: St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2015, Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO, 2015.

D. R. Cochrane, S. Bernales, B. M. Jacobsen, D. M. Cittelly, E. N. Howe et al., Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide, Breast Cancer Research, vol.3, issue.1, 2014.
DOI : 10.1158/2159-8290.CD-13-0142

. Intra, Outcome of Special Types of Luminal Breast Cancer, Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO, vol.23, issue.6, pp.1428-1464, 2012.

L. C. Collins, K. S. Cole, J. D. Marotti, R. Hu, S. J. Schnitt et al., Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study, Modern Pathology, vol.10, issue.7, pp.924-955, 2011.
DOI : 10.1093/jnci/djp082

E. J. Cops, T. Bianco-miotto, N. L. Moore, C. L. Clarke, S. N. Birrell et al., Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors, The Journal of Steroid Biochemistry and Molecular Biology, vol.110, issue.3-5, pp.3-5, 2008.
DOI : 10.1016/j.jsbmb.2007.10.014

P. Cortazar, L. Zhang, M. Untch, K. Mehta, J. P. Costantino et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, The Lancet, vol.384, issue.9938, pp.164-72, 2014.
DOI : 10.1016/S0140-6736(13)62422-8

C. Criscitiello, D. Disalvatore, M. De-laurentiis, L. Gelao, L. Fumagalli et al., High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer, The Breast, vol.23, issue.1, pp.69-75, 2014.
DOI : 10.1016/j.breast.2013.11.007

. Cuenca-lópez, D. María, C. Juan, J. C. Montero, A. Morales et al., Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling, BMC Cancer, vol.13, issue.1, pp.302-312, 2014.
DOI : 10.1186/bcr2858

J. F. Forbes and A. Latte, Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 10-Year Analysis of the ATAC Trial, The Lancet. Oncology, vol.11, issue.1210, pp.1135-1176, 2010.

D. Silva, S. Leonard, L. Parry, P. Reid, N. Keith et al., Aberrant Expression of E-cadherin in Lobular Carcinomas of the Breast, The American Journal of Surgical Pathology, vol.32, issue.5, pp.773-83, 2008.
DOI : 10.1097/PAS.0b013e318158d6c5

T. S. Dabakuyo, F. Bonnetain, P. Roignot, M. Poillot, G. Chaplain et al., Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival, Annals of Oncology, vol.19, issue.2, pp.276-83, 2008.
DOI : 10.1093/annonc/mdm491

C. Davies, H. Pan, J. Godwin, R. Gray, R. Arriagada et al., Long-Term Effects of Continuing Adjuvant Tamoxifen to 10, 2013.

D. Amicis, J. Francesca, Y. Thirugnansampanthan, J. Cui, A. Selever et al., Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells, Breast Cancer Research and Treatment, vol.90, issue.10, pp.1-11, 2010.
DOI : 10.1007/s10549-009-0436-8

E. De-azambuja, F. Cardoso, G. De-castro, M. Colozza, M. S. Mano et al., Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12???155 patients, British Journal of Cancer, vol.27, issue.10, pp.1504-1517, 2007.
DOI : 10.1002/1097-0142(19910115)67:2<421::AID-CNCR2820670217>3.0.CO;2-Q

J. M. Avril, M. Coindre, and . Trojani, Obvious Peritumoral Emboli: An Elusive Prognostic Factor Reappraised. Multivariate Analysis of 1320 Node-Negative Breast Cancers, European Journal of Cancer, vol.34, issue.1, pp.58-65, 1990.

S. Wessels and . Rodenhuis, Concordance of Clinical and Molecular Breast Cancer Subtyping in the Context of Preoperative Chemotherapy Response, Breast Cancer Research and Treatment, vol.119, issue.1, pp.119-145, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00535389

L. T. Dengel, J. Kimberly, T. A. Van-zee, M. King, H. S. Stempel et al., Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy, Annals of Surgical Oncology, vol.205, issue.1, pp.22-27, 2014.
DOI : 10.1245/s10434-013-3200-6

C. Desmedt, B. Haibe-kains, P. Wirapati, M. Buyse, D. Larsimont et al., Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes, Clinical Cancer Research, vol.14, issue.16, pp.5158-65, 2008.
DOI : 10.1158/1078-0432.CCR-07-4756

A. S. Doane, M. Danso, P. Lal, M. Donaton, L. Zhang et al., An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen, Oncogene, vol.62, issue.28, pp.3994-4008, 2006.
DOI : 10.1038/sj.onc.1209415

M. Dowsett, T. O. Nielsen, R. A. Hern, J. Bartlett, R. C. Coombes et al., Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group, JNCI Journal of the National Cancer Institute, vol.103, issue.22, pp.1656-64, 2011.
DOI : 10.1093/jnci/djr393

C. Early-breast, . Trialists-'collaborative, . Group, S. Ebctcg-), P. Darby et al., Effect of Radiotherapy after Breast- Conserving Surgery on 10-Year Recurrence and 15-Year Breast Cancer Death: Meta-Analysis of Individual Patient Data for 10,801 Women in 17 Randomised Trials, Lancet, issue.980411, pp.378-1707, 2011.

D. Clarke, S. Cutter, and . Darby, Relevance of Breast Cancer Hormone Receptors and Other Factors to the Efficacy of Adjuvant Tamoxifen: Patient-Level Meta-Analysis of Randomised Trials, Lancet, issue.979311, pp.378-771, 2011.

H. C. Gray, M. Pan, and . Clarke, Comparisons between Different Polychemotherapy Regimens for Early Breast Cancer: Meta-Analyses of Long-Term Outcome among 100, p.0, 2012.

P. Mcgale, C. Taylor, C. Correa, D. Cutter, F. Duane et al., Effect of Radiotherapy after Mastectomy and Axillary Surgery on 10-Year Recurrence and 20-Year Breast Cancer Mortality: Meta-Analysis of Individual Patient Data for 8135 Women in 22 Randomised Trials, EBCTCG (Early Breast Cancer Trialists' Collaborative Group), pp.383-2127, 2014.

F. Elloumi, Z. Hu, Y. Li, J. S. Parker, M. L. Gulley et al., Systematic Bias in Genomic Classification Due to Contaminating Non-neoplastic Tissue in Breast Tumor Samples, BMC Medical Genomics, vol.14, issue.10, pp.54-64, 2011.
DOI : 10.1158/1078-0432.CCR-07-4723

C. W. Elston and I. O. Ellis, pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.9, issue.5, pp.403-413, 1991.
DOI : 10.1016/0277-5379(88)90171-X

L. J. Esserman, A. Donald, M. C. Berry, C. Cheang, C. M. Yau et al., Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657), Breast Cancer Research and Treatment, vol.102, issue.18, pp.1049-62, 2012.
DOI : 10.1007/s10549-011-1895-2

P. Farmer, H. Bonnefoi, V. Becette, M. Tubiana-hulin, P. Fumoleau et al., Identification of molecular apocrine breast tumours by microarray analysis, Oncogene, vol.268, issue.29, pp.4660-71, 2005.
DOI : 10.1023/A:1006356502820

J. Ferlay, E. Steliarova-foucher, J. Lortet-tieulent, S. Rosso, J. W. Coebergh et al., Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, European Journal of Cancer, vol.49, issue.6, pp.1374-1403, 2013.
DOI : 10.1016/j.ejca.2012.12.027

P. L. Fitzgibbons, D. L. Page, D. Weaver, A. D. Thor, D. C. Allred et al., Prognostic Factors in Breast Cancer, College of American Pathologists Consensus Statement Archives of Pathology & Laboratory Medicine, vol.124, issue.7, pp.966-78, 1999.

K. Fizazi, I. Howard, A. Scher, . Molina, J. Christopher et al., Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301, 2012.

D. Randomised, Placebo-Controlled Phase 3 Study, The Lancet Oncology, vol.13, issue.1012, pp.983-92

P. A. Francis, M. Meredith, G. F. Regan, I. Fleming, E. Láng et al., Adjuvant Ovarian Suppression in Premenopausal Breast Cancer, New England Journal of Medicine, vol.372, issue.5, pp.436-482, 2015.
DOI : 10.1056/NEJMoa1412379

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341825

J. C. Friedland, L. Donald, J. Smith, J. Sang, S. Acquaviva et al., Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes, Investigational New Drugs, vol.3, issue.Suppl, pp.14-24, 2014.
DOI : 10.1007/s10637-013-9971-6

Z. Gatalica, Immunohistochemical Analysis of Apocrine Breast Lesions. Consistent over-Expression of Androgen Receptor Accompanied by the Loss of Estrogen and Progesterone Receptors in Apocrine Metaplasia and Apocrine Carcinoma in Situ, Pathology, Research and Practice, vol.1931297, issue.11, pp.753-58, 1997.
DOI : 10.1016/s0344-0338(97)80053-2

E. P. Gelmann, Molecular Biology of the Androgen Receptor, Journal of Clinical Oncology, vol.20, issue.13, pp.3001-3016, 2002.
DOI : 10.1200/JCO.2002.10.018

J. Gerdes, H. Lemke, H. Baisch, H. H. Wacker, U. Schwab et al., Cell Cycle Analysis of a Cell Proliferation-Associated Human Nuclear Antigen Defined by the Monoclonal Antibody Ki-67, The Journal of Immunology, vol.133, issue.4, pp.1710-1725, 1984.

L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch et al., Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort, The Lancet, vol.375, issue.9712, pp.375-377, 2010.
DOI : 10.1016/S0140-6736(09)61964-4

L. Gianni, T. Pienkowski, Y. Im, L. Tseng, M. Liu et al., 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial, The Lancet Oncology, vol.17, issue.6, pp.791-800, 2016.
DOI : 10.1016/S1470-2045(16)00163-7

D. Gillatt, Antiandrogen treatments in locally advanced prostate cancer: are they all the same?, Journal of Cancer Research and Clinical Oncology, vol.45, issue.S1, pp.17-26, 2006.
DOI : 10.1007/s00432-006-0133-5

A. Goldhirsch, E. P. Winer, A. S. Coates, R. D. Gelber, M. Piccart-gebhart et al., Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Annals of Oncology, vol.24, issue.9, pp.2206-2229, 2013.
DOI : 10.1093/annonc/mdt303

A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thürlimann et al., Senn, and Panel members Strategies for Subtypes--Dealing with the Diversity of Breast Cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Annals of Oncology: Official Journal of the European Society for Medical Oncology, issue.8, pp.22-1736, 2011.

A. M. Gonzalez-angulo, K. Stemke-hale, S. L. Palla, M. Carey, R. Agarwal et al., Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer, Clinical Cancer Research, vol.15, issue.7, pp.2472-78, 2009.
DOI : 10.1158/1078-0432.CCR-08-1763

A. Gucalp, S. Tolaney, S. J. Isakoff, J. N. Ingle, M. C. Liu et al., Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer, Clinical Cancer Research, vol.19, issue.19, pp.5505-5517, 2013.
DOI : 10.1158/1078-0432.CCR-12-3327

M. Guedj, L. Marisa, A. De-reynies, B. Orsetti, R. Schiappa et al., A refined molecular taxonomy of breast cancer, Oncogene, vol.10, issue.9, pp.1196-1206, 2012.
DOI : 10.1038/nature09515

URL : https://hal.archives-ouvertes.fr/inserm-00611752

S. Guiu, S. Michiels, F. André, J. Cortes, C. Denkert et al., Molecular Subclasses of Breast Cancer: How Do We Define Them? The IMPAKT 2012, 2012.

. Haibe-kains, C. Benjamin, S. Desmedt, A. C. Loi, G. Culhane et al., A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes, JNCI Journal of the National Cancer Institute, vol.104, issue.4, pp.311-336, 2012.
DOI : 10.1093/jnci/djr545

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283537

S. Hagerty, P. L. Badve, and . Fitzgibbons, College Of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer, American Society of Clinical Oncology Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.28, issue.16, pp.2784-95, 2010.

T. Hara, J. Miyazaki, H. Araki, M. Yamaoka, N. Kanzaki et al., Novel Mutations of Androgen Receptor: A Possible Mechanism of Bicalutamide Withdrawal Syndrome, Cancer Research, vol.63, issue.1, pp.149-53, 2003.

J. He, R. Peng, Z. Yuan, S. Wang, J. Peng et al., Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray, Medical Oncology, vol.4, issue.24, pp.406-416, 2012.
DOI : 10.1007/s12032-011-9832-0

S. Gilcrease, J. Krishnamurthy, J. Lee, and . Fridlyand, Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics, Cancer Research, vol.69, issue.10, pp.4116-4140, 2009.

J. I. Herschkowitz, K. Simin, V. J. Weigman, I. Mikaelian, J. Usary et al., Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors, Genome Biology, vol.8, issue.5, pp.76-86, 2007.
DOI : 10.1186/gb-2007-8-5-r76

D. L. Hershman, H. Lawrence, T. Kushi, D. Shao, A. Buono et al., Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients, Journal of Clinical Oncology, vol.28, issue.27, pp.4120-4148, 2010.
DOI : 10.1200/JCO.2009.25.9655

. Tamimi, Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women Clinical Cancer Research, An Official Journal of the American Association for Cancer Research, vol.17, issue.7, pp.1867-74, 2011.

Z. Hu, C. Fan, S. Daniel, . Oh, X. Js-marron et al., The Molecular Portraits of Breast Tumors Are Conserved across Microarray Platforms, BMC Genomics, vol.7, issue.1, pp.96-106, 2006.
DOI : 10.1186/1471-2164-7-96

J. W. Pritchard, J. A. Chapman, and . Sparano, Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.25, issue.15, pp.2127-2159, 2007.

J. Hugh, J. Hanson, M. Chon, U. Cheang, T. O. Nielsen et al., Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial, Journal of Clinical Oncology, vol.27, issue.8, pp.1168-76, 2009.
DOI : 10.1200/JCO.2008.18.1024

R. D. Iggo, New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours, Breast Cancer Research, vol.364, issue.6, pp.318-328, 2011.
DOI : 10.1056/NEJMoa1014618

T. Iwamoto, D. Booser, V. Valero, J. L. Murray, K. Koenig et al., Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry, Journal of Clinical Oncology, vol.30, issue.7, pp.729-763, 2012.
DOI : 10.1200/JCO.2011.36.2574

C. Kadoch, D. C. Hargreaves, C. Hodges, L. Elias, L. Ho et al., Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy, Nature Genetics, vol.460, issue.6, pp.592-601, 2013.
DOI : 10.1128/MCB.02019-07

P. Kastner, A. Krust, B. Turcotte, U. Stropp, L. Tora et al., Two Distinct Estrogen-Regulated Promoters Generate Transcripts Encoding the Two Functionally Different Human Progesterone Receptor Forms A and B, The EMBO Journal, vol.9, issue.5, pp.1603-1617, 1990.

F. Klauschen, S. Wienert, W. D. Schmitt, S. Loibl, B. Gerber et al., Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study, Clinical Cancer Research, vol.21, issue.16, 2014.
DOI : 10.1158/1078-0432.CCR-14-1283

J. Mihatsch, G. Sauter, and O. P. Kallioniemi, Tissue Microarrays for High-Throughput Molecular Profiling of Tumor Specimens, Nature Medicine, vol.4, issue.7, pp.844-891, 1998.

E. L. Korn, M. C. Sachs, and L. M. Mcshane, Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer, Annals of Oncology, vol.27, issue.1, pp.10-15, 2016.
DOI : 10.1093/annonc/mdv507

M. Korpal, J. M. Korn, X. Gao, D. P. Rakiec, D. A. Ruddy et al., An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide), Cancer Discovery, vol.3, issue.9, pp.1030-1073, 2013.
DOI : 10.1158/2159-8290.CD-13-0142

J. A. Kraus, J. David, S. Dabbs, R. Beriwal, and . Bhargava, Semi-quantitative immunohistochemical assay versus oncotype DX?? qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study, Modern Pathology, vol.19, issue.6, pp.869-76, 2012.
DOI : 10.3109/07357907.2010.496754

V. Kumar, S. Green, G. Stack, M. Berry, J. R. Jin et al., Functional domains of the human estrogen receptor, Cell, vol.51, issue.6, pp.941-51, 1987.
DOI : 10.1016/0092-8674(87)90581-2

S. R. Lakhani, International Agency for Research on Cancer, and World Health Organization WHO Classification of Tumours of the Breast World Health Organization Classification of Tumours, International Agency for Research on Cancer, 2012.

S. Lakis, V. Kotoula, A. G. Eleftheraki, A. Batistatou, M. Bobos et al., The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping, The Breast, vol.23, issue.3, p.23, 2014.
DOI : 10.1016/j.breast.2014.02.013

. Blamey, Prognostic Value of Lymphovascular Invasion in Women with Lymph Node Negative Invasive Breast Carcinoma, European Journal of Cancer, vol.42, issue.3, pp.357-62, 2006.

H. Lee and C. Chang, Recent advances in androgen receptor action, Cellular and Molecular Life Sciences (CMLS), vol.60, issue.8, pp.1613-1635, 2003.
DOI : 10.1007/s00018-003-2309-3

B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. Bapsi-chakravarthy et al., Identification of Human Triple-Negative Breast, 2011.

B. D. Lehmann, J. A. Bauer, J. M. Schafer, C. S. Pendleton, L. Tang et al., PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors, Breast Cancer Research, vol.19, issue.4, 2014.
DOI : 10.1158/1078-0432.CCR-12-3327

J. Lehmann-che, A. Hamy, R. Porcher, M. Barritault, F. Bouhidel et al., Molecular Apocrine Breast Cancers Are Aggressive Estrogen Receptor Negative Tumors Overexpressing Either HER2 or GCDFP15 Les Données -Institut National Du Cancer, Breast Cancer Research: BCR Accessed August, vol.15, issue.3, 2013.
DOI : 10.1186/bcr3421

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053236

W. F. Mejia and . Symmans, Response to Neoadjuvant Therapy and Long-Term Survival in Patients with Triple-Negative Breast Cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.26, issue.8, pp.1275-81, 2008.

E. Lim, M. Ni, S. Cao, A. Hazra, R. M. Tamimi et al., Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy, Current Breast Cancer Reports, vol.375, issue.9724, pp.71-78, 2014.
DOI : 10.1007/s12609-014-0140-5

M. Asselin-labat, Aberrant Luminal Progenitors as the Candidate Target Population for Basal Tumor Development in BRCA1 Mutation Carriers, Nature Medicine, vol.15, issue.8, pp.907-920, 2000.

C. Tutt, P. Gillet, and . Ellis, Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor?Positive Breast Carcinomas Through Genomic Grade, Journal of Clinical Oncology, vol.25, issue.10, pp.1239-1285, 2007.

S. Loibl, M. Müller, M. Gunter-von-minckwitz, M. Schwabe, S. Roller et al., Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy, Breast Cancer Research and Treatment, vol.28, issue.6, pp.477-87, 2011.
DOI : 10.1007/s10549-011-1715-8

M. Loo, M. Van-der-heiden-van-der, V. K. Schaapveld, S. Ho, E. J. Siesling et al., Outcomes of a Population-Based Series of Early Breast Cancer Patients with Micrometastases and Isolated Tumour Cells in Axillary Lymph Nodes, Annals of Oncology, vol.24, issue.11, pp.2794-2801, 2013.

. Brodie, Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole, Cancer Research, vol.66, issue.15, pp.7775-82, 2006.

A. Vincent-salomon, P. Roger, and I. Treilleux, [Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France], 2014.

S. P. David, M. Tan, A. Dowsett, J. S. Ashworth, and . Reis-filho, Microarray- Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement, Journal of the National Cancer Institute, vol.103, issue.8, pp.662-73, 2011.

M. Tubiana-hulin and S. Chan, Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined with Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered as First-Line Treatment: The M77001 Study Group, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.23, pp.4265-74, 2005.

H. Masuda, K. A. Baggerly, Y. Wang, Y. Zhang, A. M. Gonzalez-angulo et al., Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes, Clinical Cancer Research, vol.19, issue.19, pp.5533-5573, 2013.
DOI : 10.1158/1078-0432.CCR-13-0799

K. M. Mcnamara, T. Yoda, K. Takagi, Y. Miki, T. Suzuki et al., Androgen receptor in triple negative breast cancer, The Journal of Steroid Biochemistry and Molecular Biology, vol.133, pp.66-76, 2013.
DOI : 10.1016/j.jsbmb.2012.08.007

F. Sessa, Androgen Receptor Is Frequently Expressed in HER2-Positive, ER/PR- Negative Breast Cancers, Virchows Archiv: An International Journal of Pathology, vol.457, issue.4, 2010.

J. S. Mieog, J. A. Van-der-hage, and C. J. Van-de-velde, Preoperative chemotherapy for women with operable breast cancer, The Cochrane Database of Systematic Reviews, vol.30, issue.22, 2007.
DOI : 10.1002/14651858.CD005002

. Milanes-yearsley, M. Martha, . H. Elizabeth, T. F. Hammond, J. S. Pajak et al., Tissue Micro-Array: A Cost and Time-Effective Method for Correlative Studies by Regional and National Cancer Study Groups, Modern Pathology, vol.15, issue.12, pp.1366-73, 2002.
DOI : 10.1097/01.MP.0000036345.18944.22

. Atkins, Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers, The American Journal of Surgical Pathology, vol.40, issue.8, pp.1109-1125, 2016.

P. A. Eidtmann, B. Fasching, and . Gerber, Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes, Journal of Clinical Oncology, vol.30, issue.15, pp.1796-1804, 2012.

A. Gerard, A. A. Tarulli, and . Serandour, Progesterone Receptor Modulates ER? Action in Breast Cancer, Nature, vol.523, issue.7560, pp.313-330, 2015.

P. S. Wohlfahrt, O. P. Nykänen, J. J. Törmäkangas, P. J. Palvimo, and . Kallio, Discovery of ODM-201, a New-Generation Androgen Receptor Inhibitor Targeting Resistance Mechanisms to Androgen Signaling-Directed Prostate Cancer Therapies, Scientific Reports, vol.5, p.12007, 2015.

A. Naderi, K. M. Chia, and J. Liu, Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer, Breast Cancer Research, vol.70, issue.2, pp.36-46, 2011.
DOI : 10.1158/0008-5472.CAN-09-1845

A. Naderi and L. Hughes-davies, A Functionally Significant Cross-Talk between, 2008.

S. A. Narod, Tumour size predicts long-term survival among women with lymph node-positive breast cancer, Current Oncology, vol.19, issue.5, pp.249-53, 2012.
DOI : 10.3747/co.19.1043

URL : http://doi.org/10.3747/co.19.1043

M. Ni, Y. Chen, T. Fei, D. Li, E. Lim et al., Amplitude modulation of androgen signaling by c-MYC, Genes & Development, vol.27, issue.7, 2013.
DOI : 10.1101/gad.209569.112

X. S. Rimm, M. Liu, and . Brown, Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer, Cancer Cell, vol.20, issue.1, pp.119-150, 2011.

T. O. Nielsen, D. Forrest, K. Hsu, M. Jensen, G. Cheang et al., Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma, Clinical Cancer Research, vol.10, issue.16, pp.5367-74, 2004.
DOI : 10.1158/1078-0432.CCR-04-0220

S. R. Davies, A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer Clinical Cancer Research, An Official Journal of the American Association for Cancer Research, vol.16, issue.21, pp.5222-5254, 2010.

L. A. Niemeier, J. David, S. Dabbs, J. M. Beriwal, R. Striebel et al., Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation, Modern Pathology, vol.10, issue.2, 2010.
DOI : 10.1016/S0002-9610(03)00054-0

V. C. Njar and A. M. Brodie, Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer, Journal of Medicinal Chemistry, vol.58, issue.5, pp.2077-87, 2015.
DOI : 10.1021/jm501239f

O. Pagani, M. M. Regan, B. A. Walley, G. F. Fleming, M. Colleoni et al., Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer, New England Journal of Medicine, vol.371, issue.2, pp.107-125, 2014.
DOI : 10.1056/NEJMoa1404037

S. Park, J. Koo, H. S. Park, J. Kim, S. Choi et al., Expression of androgen receptors in primary breast cancer, Annals of Oncology, vol.21, issue.3, pp.488-92, 2010.
DOI : 10.1093/annonc/mdp510

J. S. Parker, M. Mullins, M. C. Cheang, S. Leung, D. Voduc et al., Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes, Journal of Clinical Oncology, vol.27, issue.8, pp.1160-67, 2009.
DOI : 10.1200/JCO.2008.18.1370

D. Du, G. Pour, and L. , évaluation Du Statut HER2 Dans Les Cancers Du Sein En France, Annales de Pathologie, vol.34, issue.5, pp.352-65

C. M. Perou, T. Sørlie, M. B. Eisen, M. Van-de-rijn, S. S. Jeffrey et al., Molecular Portraits of Human Breast Tumours, Nature, vol.406, issue.6797, pp.747-52, 2000.
DOI : 10.1038/35021093

C. M. Perou, T. Sørlie, M. B. Eisen, M. Van-de-rijn, S. S. Jeffrey et al., Molecular Portraits of Human Breast Tumours, Nature, vol.406, issue.6797, pp.747-52, 2000.
DOI : 10.1038/35021093

L. Perreard, C. Fan, J. F. Quackenbush, M. Mullins, N. P. Gauthier et al., Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay, Breast Cancer Research, vol.65, issue.Part 3, pp.23-33, 1399.
DOI : 10.1158/0008-5472.CAN-04-3617

J. M. Centenera, S. Harris, and . Jindal, Androgen Receptor Inhibits Estrogen Receptor-Alpha Activity and Is Prognostic in Breast Cancer, Cancer Research, vol.69, issue.15, pp.6131-6171, 2009.

M. J. Piccart-gebhart, M. Procter, B. Leyland-jones, A. Goldhirsch, M. Untch et al., Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1659-72, 2005.
DOI : 10.1056/NEJMoa052306

A. Prat, O. Parker, C. Karginova, C. Fan, . Livasy et al., Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Research, vol.15, issue.1, pp.10-1186, 2010.
DOI : 10.1038/nm0809-842

. Traina, Targeting the Androgen Receptor in Prostate and Breast Cancer: Several New Agents in Development, Endocrine-Related Cancer, vol.22, issue.3, pp.87-106, 2015.

T. M. Prowell and R. Pazdur, Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2438-2479, 2012.
DOI : 10.1056/NEJMp1205737

F. Ragage, M. Debled, G. Macgrogan, V. Brouste, M. Desrousseaux et al., Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?, Cancer, vol.23, issue.suppl, pp.3093-3101, 2010.
DOI : 10.1002/cncr.25137

Z. Grainge, R. W. Hodi, I. O. Blamey, and . Ellis, Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma, Journal of Clinical Oncology, vol.26, pp.3153-58, 2008.

M. Rampurwala, K. B. Wisinski, and R. Regan, Role of the Androgen Receptor in Triple-Negative Breast Cancer, Clinical Advances in Hematology & Oncology: H&O, vol.14, issue.3, pp.186-93, 2016.

P. J. Hager and . Rix, Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, issue.28, pp.31-3525, 2013.

J. R. Rivkin, R. J. Borst, and . Belt, Prognostic Significance of Progesterone Receptor Levels in Estrogen Receptor-Positive Patients with Metastatic Breast Cancer Treated with Tamoxifen: Results of a Prospective Southwest Oncology Group Study, Journal of Clinical Oncology, vol.10, issue.8, pp.1284-91, 1992.

N. L. Weigel, B. W. Malley, P. H. Brown, and S. A. Fuqua, AR Collaborates with ER? in Aromatase Inhibitor-Resistant Breast Cancer, Breast Cancer Research and Treatment, vol.147, issue.3, pp.473-85, 2014.

M. M. Regan, A. Patrick-neven, A. Giobbie-hurder, B. Goldhirsch, L. Ejlertsen et al., Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8??1 years median follow-up, The Lancet Oncology, vol.12, issue.12, pp.1101-1109, 2011.
DOI : 10.1016/S1470-2045(11)70270-4

J. K. Richer, M. Britta, N. G. Jacobsen, M. G. Manning, D. M. Abel et al., Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells, Journal of Biological Chemistry, vol.277, issue.7, pp.5209-5227, 2002.
DOI : 10.1074/jbc.M110090200

D. Amicis and L. Mauro, Estrogen Receptor Beta as a Novel Target of Androgen Receptor Action in Breast Cancer Cell Lines, Breast Cancer Research: BCR, vol.16, issue.1, 2014.

I. G. Neal, J. S. Mills, and . Carroll, Androgen Receptor Driven Transcription in Molecular Apocrine Breast Cancer Is Mediated by FoxA1, The EMBO Journal, vol.30, issue.15, pp.3019-3046, 2011.

E. Davidson and . Tan-chiu, Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, The New England Journal of Medicine, vol.353, issue.16, pp.1673-84, 2005.

P. Logothetis, K. De-souza, and . Fizazi, Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy, The New England Journal of Medicine, vol.368, issue.2, 2013.

. Linthorst, Influence of Tumour Stage at Breast Cancer Detection on Survival in Modern Times: Population Based Study in 173 797 Patients, The BMJ, vol.351, 2015.

D. Safarpour, S. Pakneshan, and F. A. Tavassoli, Androgen Receptor (AR) Expression in 400 Breast Carcinomas: Is Routine AR Assessment Justified, 2014.

S. Sanga, B. M. Broom, V. Cristini, and M. E. Edgerton, Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family, BMC Medical Genomics, vol.32, issue.Unit 7, pp.59-69, 2009.
DOI : 10.1109/TSMCA.2002.803772

H. I. Scher, K. Fizazi, F. Saad, M. Taplin, C. N. Sternberg et al., Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, New England Journal of Medicine, vol.367, issue.13, pp.1187-97, 2012.

E. Senkus, S. Kyriakides, S. Ohno, F. Penault-llorca, P. Poortmans et al., Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, issue.suppl 5, pp.8-30, 2015.
DOI : 10.1093/annonc/mdv298

R. Seshadri, C. Matthews, A. Dobrovic, and D. J. Horsfall, The significance of oncogene amplification in primary breast cancer, International Journal of Cancer, vol.47, issue.2, pp.270-72, 1989.
DOI : 10.1002/ijc.2910430218

S. P. Shah, A. Roth, R. Goya, A. Oloumi, G. Ha et al., The clonal and mutational evolution spectrum of primary triple-negative breast cancers, Nature, vol.464, issue.7403, pp.395-9910, 1038.
DOI : 10.1038/nature10933

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, 2015, CA: A Cancer Journal for Clinicians, vol.61, issue.3, pp.5-29, 2015.
DOI : 10.3322/caac.21254

J. Jegal, The Role of Lymphovascular Invasion as a Prognostic Factor in Patients with Lymph Node-Positive Operable Invasive Breast Cancer, Journal of Breast Cancer, vol.14, issue.3, pp.198-203, 2011.

T. Sørlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.98, issue.19, pp.10869-74, 2001.
DOI : 10.1073/pnas.191367098

S. Deng, Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets, Proceedings of the National Academy of Sciences of the United States of America, vol.100, issue.14, pp.8418-8441, 2003.

S. Wedge and . Nik-zainal, The Landscape of Cancer Genes and Mutational Processes in Breast Cancer, Nature, vol.486, issue.7403, pp.400-404, 2012.

F. A. Tavassoli and P. Devilee, International Agency for Research on Cancer, and World Health Organization Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours, 2003.

S. Terry, X. Yang, M. Chen, F. Vacherot, and R. Buttyan, Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer, Journal of Cellular Biochemistry, vol.61, issue.2, pp.402-412, 2006.
DOI : 10.1002/jcb.20983

URL : https://hal.archives-ouvertes.fr/inserm-00106395

S. M. Tolaney, T. William, C. T. Barry, D. A. Dang, B. Yardley et al., Adjuvant Paclitaxel and Trastuzumab for, 2015.

H. Negative, Positive Breast Cancer, The New England Journal of Medicine, vol.372, issue.2, pp.134-175, 1406281.

P. J. Toren, S. Kim, S. Pham, A. Mangalji, H. Adomat et al., Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer, Molecular Cancer Therapeutics, vol.14, issue.1, pp.59-69, 2015.
DOI : 10.1158/1535-7163.MCT-14-0521

C. Tran, S. Ouk, N. J. Clegg, Y. Chen, P. A. Watson et al., Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer, Science, vol.324, issue.5928, pp.324-787, 2009.
DOI : 10.1126/science.1168175

C. H. Van-deurzen, E. M. Maaike-de-boer, P. Monninkhof, E. Bult, V. C. Van-der-wall et al., Non-Sentinel Lymph, 2008.

E. Amir, Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis, Journal of the National Cancer Institute, vol.106, issue.1, 2014.

G. Mazzarol, Predicting the Risk for Additional Axillary Metastases in Patients With Breast Carcinoma and Positive Sentinel Lymph Node Biopsy, Annals of Surgery, vol.241, issue.2, pp.319-344, 2005.

S. Vranic, C. Marchiò, I. Castellano, C. Botta, M. S. Scalzo et al., Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast, Human Pathology, vol.46, issue.9, 2015.
DOI : 10.1016/j.humpath.2015.05.017

S. Vranic, O. Tawfik, J. Palazzo, N. Bilalovic, E. Eyzaguirre et al., EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast, Modern Pathology, vol.33, issue.5, pp.644-53, 2010.
DOI : 10.1111/j.1699-0463.1999.tb01546.x

P. A. Watson, F. Yinan, M. D. Chen, J. Balbas, N. D. Wongvipat et al., Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor, Proceedings of the National Academy of Sciences, vol.107, issue.39, pp.16759-65, 2010.
DOI : 10.1073/pnas.1012443107

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947883

M. J. Jong, L. J. Van-de-vijver, . Van-'t, J. L. Veer, and . Peterse, Refinement of Breast Cancer Classification by Molecular Characterization of Histological Special Types, The Journal of Pathology, vol.216, issue.2, pp.141-50, 2008.

S. R. Wellings, H. M. Jensen, and R. G. Marcum, An Atlas of Subgross Pathology of the Human Breast with Special Reference to Possible Precancerous Lesions, Journal of the National Cancer Institute, vol.55, issue.2, pp.231-73, 1975.

T. J. Whelan, . Jean-philippe, M. N. Pignol, J. A. Levine, R. Julian et al., Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer, New England Journal of Medicine, vol.362, issue.6, pp.513-533, 2010.
DOI : 10.1056/NEJMoa0906260

K. H. Mcshane, D. C. Allison, and . Allred, Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerCollege of American Pathologists Clinical Practice Guideline Update, Journal of Clinical Oncology, vol.31, issue.31, pp.3997-4013, 2013.

S. Yamamoto, Z. Wu, H. G. Russnes, S. Takagi, G. Peluffo et al., JARID1B Is a Luminal Lineage-Driving Oncogene in Breast Cancer, Cancer Cell, vol.25, issue.6, pp.762-77, 2014.
DOI : 10.1016/j.ccr.2014.04.024

C. Tudor and S. Stopatschinskaja, A Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Evaluating the Efficacy and Safety of Enzalutamide in Combination with Exemestane in Estrogen or Progesterone Receptor-Positive and HER2- Normal Advanced Breast Cancer, Journal of Clinical Oncology, vol.32, p.5, 2014.

K. Yu, R. Zhu, M. Zhan, A. A. Rodriguez, W. Yang et al., Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer, Clinical Cancer Research, vol.19, issue.10, pp.2723-2756, 2013.
DOI : 10.1158/1078-0432.CCR-12-2986